Evidence map›Paper›PMID 26152579›Full record

ArticlePeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis2015

Effects of a Statewide Protocol for the Management of Peritoneal Dialysis-Related Peritonitis on Microbial Profiles and Antimicrobial Susceptibilities: A Retrospective Five-Year Review.

Amanda L McGuire, Christine F Carson, Timothy J J Inglis, Aron Chakera

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antimicrobial resistance in nephrology.Nature reviews. Nephrology · 2019
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Amanda L McGuireHarry Perkins Institute of Medical Research, Nedlands, Western Australia School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia.
Christine F CarsonHarry Perkins Institute of Medical Research, Nedlands, Western Australia School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia.
Timothy J J InglisDepartment of Microbiology, PathWest Laboratory Medicine WA, Nedlands, Western Australia School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia.
Aron ChakeraHarry Perkins Institute of Medical Research, Nedlands, Western Australia School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia Renal Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia aron.chakera@uwa.edu.au.
Harry Perkins Institute of Medical Research · AUPathwest Laboratory Medicine · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled♦

backgroundPeritonitis is a major complication of peritoneal dialysis (PD) and is associated with significant morbidity and mortality. Early empirical antibiotic therapy is recommended, with the choice of agents guided by local resistance patterns. As routine use of specific antimicrobial agents can drive resistance, regular assessment of causative organisms and their susceptibility to empirical therapy is essential. ♦

methodsWe conducted a retrospective review of all PD peritonitis cases and positive PD fluid cultures obtained over a 5-year period in Western Australia following the introduction of a statewide protocol for the initial management of PD peritonitis with intraperitoneal vancomycin and gentamicin. ♦

resultsThe incidence of PD peritonitis decreased from 1 in 16 patient months (0.75/year at risk) to 1 in 29 patient months (0.41/year at risk) over the 5 years. There were 1,319 culture-positive samples and 1,069 unique isolates identified. Gram-positive bacteria accounted for 69.9% of positive cultures, with vancomycin resistance averaging 2% over the study period. Gram-negative bacteria accounted for 25.4% of positive cultures, with gentamicin resistance identified in an average of 8% of organisms. No increase in antimicrobial resistance to vancomycin or gentamicin occurred over the 5 years and there was no change in the proportion of gram-positive (69.9%), gram-negative (25.4%) or fungal (4.4%) organisms causing PD peritonitis. ♦

conclusionsOver time, the peritonitis rates have dramatically improved although the profile of causative organisms remains similar. Empirical treatment of PD peritonitis with intraperitoneal vancomycin and gentamicin remains efficacious, with high levels of susceptibility and no evidence that the introduction of this statewide empirical PD peritonitis treatment protocol is driving resistance to these agents.

Indexed as

Drug Resistance, BacterialAdultAnti-Bacterial AgentsAustraliaClinical ProtocolsFemaleHumansKidney Failure, ChronicMalePeritoneal DialysisPeritonitisRetrospective StudiesAnti-Bacterial Agentsempirical therapygentamicinPeritonitisresistance patternsvancomycin

Identifiers

PMID26152579
PMCPMC4690627
OpenAlexW2206858116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.